uromonitor
Uromonitor
A non-invasive, urine-based molecular test used in bladder cancer diagnosis and surveillance.
Bladder cancer surveillance can place a significant burden on patients and services.
Bladder cancer surveillance today typically relies on repeated cystoscopy — an invasive and resource-intensive procedure for patients and healthcare services.
Uromonitor is positioned around a different approach: a non-invasive, urine-based molecular test intended for use in bladder cancer diagnosis and surveillance.
Position molecular testing alongside existing diagnostic and monitoring pathways within bladder cancer services.
A urine-based molecular approach to bladder cancer monitoring.
Uromonitor is a non-invasive molecular test based on a urine sample and intended for use within bladder cancer diagnosis and surveillance. Clinical performance, regulatory statements and adoption claims should remain based on approved evidence and current documentation.
Designed around the pathway, not simply the technology.
Progen brings the technology. Lifecycle brings NHS market knowledge.
UK & Ireland route
Progen Diagnostics is the vehicle through which Uromonitor is brought to and developed in the UK and Ireland.
Adoption support
Lifecycle holds a 50% share in Progen Diagnostics and contributes NHS market knowledge, pathway design, health-economic modelling, pilot development and adoption support.
Evidence first. Adoption second.
Evidence base
Clinical performance claims should be supported by approved evidence. The UK proposition is built around evidence relevant to the intended clinical use and pathway.
Clinical, economic & operational case
Lifecycle can assess the implications for patient pathways, service capacity, workforce, operational delivery and health economics when developing the UK case.
Regulatory & availability
Regulatory and availability statements should reflect current, approved documentation and should not be inferred from broader market activity or adoption.
More than distribution. A route into UK healthcare.
Want to discuss Uromonitor and its role in UK bladder cancer pathways?
Speak to the team about Uromonitor, the UK proposition and how Progen Diagnostics and Lifecycle support the route from technology to healthcare adoption.